1 Classification and nomenclature

The complement component system consists of soluble proteins in plasma and membrane-associated proteins on cell surfaces. Most components circulate as inactive precursors and are activated by proteolytic cleavage. Once triggered, they participate in a stepwise cascade that amplifies the response and produces a range of immune effects.

Complement proteins are commonly designated by the letter C followed by a number, such as C1, C2, or C3. Many activated fragments are named with suffixes that indicate smaller cleavage products or functional forms. This naming system reflects both the sequence of discovery and the order in which the proteins act in the cascade.

1.1 Core complement components

The central complement proteins include C1 through C9, together with several associated factors and regulatory proteins. Among these, C3 occupies a pivotal position because its cleavage links the major activation pathways and initiates many downstream functions. C5 to C9 are especially important for membrane attack complex formation, while C1 and mannose-binding lectin-associated proteins are involved in pathway initiation.

Several accessory proteins also contribute to complement activity. These include factor B, factor D, properdin, mannose-binding lectin, and a range of regulators that shape the intensity and duration of the response. Together, these components form a network rather than a simple linear chain.

1.2 Activation fragments and naming conventions

When a complement protein is cleaved, the larger fragment is often labeled with the suffix b, while the smaller fragment receives the suffix a. In general, the larger fragment remains bound to a surface or continues in the cascade, whereas the smaller fragment diffuses away and often acts as a signaling molecule. A well-known exception is C2, where historical naming does not fully match the usual pattern.

Activated fragments have distinct biological roles. Some act as opsonins, some promote inflammation, and others assemble into membrane-damaging complexes. The fragment nomenclature therefore helps distinguish structural changes from functional outcomes.

1.3 Historical discovery and terminology

Complement was first recognized as a heat-labile serum activity that could “complement” antibody-mediated killing of microbes. Early studies revealed that serum contained factors able to enhance immune defense even in the absence of directly visible cellular participation. As the system was mapped biochemically, individual proteins were assigned the now-familiar C-numbered names.

The terminology reflects the gradual development of immunology. What began as a single serum activity was later understood as a coordinated set of proteins with separate regulatory and effector roles. This historical evolution is preserved in the naming system still used today.

2 Complement activation pathways

Complement can be activated by multiple pathways that detect different types of molecular patterns or immune complexes. Despite their distinct initiation steps, all pathways generate a common enzymatic progression that leads to C3 cleavage. This convergence allows the system to respond to a wide variety of targets while using shared downstream machinery.

2.1 Classical pathway

The classical pathway is typically initiated by antibodies bound to antigen, although other recognition molecules can also trigger it. It is closely associated with adaptive immunity because it links antigen recognition to complement activation. Once started, it proceeds through a series of ordered proteolytic events.

2.1.1 Antigen-antibody initiation

In the classical pathway, immune complexes formed by antibodies attached to antigen provide a surface that can recruit complement components. IgM is especially effective because its structure readily exposes binding sites for the first complement component after antigen engagement. Certain IgG subclasses can also support this activation when present in sufficient density.

This mechanism enables complement to amplify specific immune recognition. The system therefore acts as an effector arm of humoral immunity, translating antibody binding into broader inflammatory and lytic responses.

2.1.2 C1 complex and early cleavage steps

Activation begins when the C1 complex binds to the Fc region of antibody in an immune complex. The complex includes C1q, C1r, and C1s. Binding of C1q triggers enzymatic activation within the complex, leading to cleavage of C4 and C2.

The products of these cleavages assemble into a surface-bound convertase that cleaves C3. This early step is crucial because it creates the main amplification point for the pathway and prepares the target surface for further complement deposition.

2.2 Lectin pathway

The lectin pathway resembles the classical pathway in its downstream chemistry, but its initiation depends on direct recognition of microbial carbohydrate patterns rather than antibodies. It is an important link between innate pattern recognition and complement activation. Its function is especially relevant in early defense against infection.

2.2.1 Mannose-binding lectin recognition

Mannose-binding lectin recognizes repeating sugar structures, particularly mannose-rich carbohydrates found on many microbial surfaces. This binding allows complement activation without prior exposure to a pathogen. Other lectin pathway recognition molecules can perform similar functions in a related manner.

Because host cell surfaces usually present different carbohydrate patterns, the lectin pathway tends to favor microbial targets. This selectivity helps direct complement activity toward nonself surfaces.

2.2.2 MASP-mediated activation

Mannose-binding lectin associates with mannose-binding lectin-associated serine proteases, or MASPs. After recognition of a suitable surface, these proteases become active and cleave C4 and C2. The resulting enzyme complex is functionally similar to the classical pathway convertase.

This shared chemistry means that different initiation signals can be integrated into a common downstream response. The lectin pathway therefore broadens the range of triggers capable of mobilizing complement.

2.3 Alternative pathway

The alternative pathway can be activated without a distinct recognition molecule at the start. Instead, it depends on the spontaneous hydrolysis and turnover of C3, which permits continuous low-level surveillance. This makes the pathway a major source of amplification for complement responses.

2.3.1 Spontaneous C3 activation

C3 undergoes spontaneous low-level activation in plasma, producing fragments that can attach to nearby surfaces. If the surface lacks protective regulators, these fragments can recruit factor B and factor D, leading to formation of an active convertase. The pathway thus functions as a rapid sensing system for surfaces that do not effectively restrain complement.

This mechanism is sometimes described as “tickover.” It provides a baseline level of activation that can be expanded quickly when a target surface is encountered.

2.3.2 Amplification loop

Once the alternative pathway is engaged, newly generated C3b molecules can bind additional factor B and generate more convertase. This creates a positive feedback loop that greatly increases the amount of C3 cleavage. Properdin can stabilize the convertase and support this amplification.

The loop allows small initiating signals to produce strong biological effects. It also ensures that complement deposition can spread efficiently over a target surface.

2.4 Convergence on C3 and C5

All three major activation pathways converge at the level of C3 cleavage. The resulting C3b fragments coat surfaces, while the smaller fragment C3a contributes to inflammatory signaling. Further assembly of C5 convertase leads to cleavage of C5 and sets the stage for terminal pathway activation.

C5 cleavage is a decisive step because it initiates membrane attack complex formation. At this point, complement shifts from surface marking and signaling to direct structural damage of susceptible targets.

3 Functional roles

Complement components support immune defense through several overlapping functions. These include opsonization, inflammatory signaling, membrane injury, removal of immune complexes, and enhancement of adaptive responses. The combined effect is a coordinated system that can both identify and eliminate threats.

3.1 Opsonization

Opsonization is the coating of a target with molecules that make it easier for phagocytes to recognize and ingest. Complement is particularly effective in this role because cleavage products can bind directly to microbial surfaces. This promotes efficient clearance by cells of the innate immune system.

3.1.1 C3b and phagocytosis enhancement

C3b is the principal opsonic complement fragment. Once deposited on a target, it can be recognized by complement receptors on neutrophils, macrophages, and other phagocytic cells. This interaction improves adherence, ingestion, and subsequent destruction of the target.

Opsonization is especially important for particles that would otherwise resist phagocytosis. By decorating the surface with C3b, complement helps transform a poorly recognized target into one that is readily engulfed.

3.2 Inflammation and chemotaxis

Complement fragments also act as inflammatory mediators. They can increase vascular permeability, promote local activation of immune cells, and influence the movement of leukocytes toward a site of injury or infection. These effects connect complement activity to the broader inflammatory response.

3.2.1 Anaphylatoxins

Small cleavage fragments such as C3a, C4a, and C5a are termed anaphylatoxins. They can induce mast cell activation, smooth muscle effects, and other inflammatory changes. Among them, C5a is generally the most potent in driving cellular responses.

Anaphylatoxins function as signaling molecules that rapidly alter the local immune environment. Their effects help concentrate immune activity where complement has detected a threat.

3.2.2 Leukocyte recruitment

Complement-generated signals promote the directed movement of leukocytes to affected tissues. C5a is particularly effective as a chemoattractant for neutrophils and monocytes. By following these signals, immune cells accumulate at sites where complement has been activated.

This recruitment supports pathogen elimination and debris clearance. It also links complement activation to the visible features of inflammation such as redness, swelling, and heat.

3.3 Direct cell lysis

In certain settings, complement can kill target cells directly. This requires assembly of the terminal complement components into a structure that disrupts membrane integrity. Direct lysis is especially relevant against susceptible microbes and some antibody-coated cells.

3.3.1 Membrane attack complex formation

The membrane attack complex is formed by sequential assembly of C5b, C6, C7, C8, and multiple C9 molecules. The complex inserts into the membrane and creates a pore-like lesion. This disrupts cellular homeostasis and can lead to lysis.

The membrane attack complex is most effective against cells with exposed or vulnerable membranes. Host cells are normally protected by regulatory proteins that prevent inappropriate terminal pathway assembly.

3.4 Immune complex clearance

Complement contributes to the removal of immune complexes from circulation. When complement components bind to these complexes, they can facilitate attachment to receptors on erythrocytes and phagocytic cells. This supports transport to organs where immune complexes can be processed and cleared.

Efficient clearance reduces the persistence of circulating immune complexes and limits tissue deposition. In this way, complement helps maintain immunological balance after antibody responses have been activated.

Complement enhances adaptive immune responses in several ways. It can lower the threshold for B-cell activation, support antigen retention on follicular dendritic cells, and improve the efficiency of antibody responses. These effects make complement an important bridge between innate and adaptive immunity.

The system also influences the quality of immune memory by shaping antigen handling and lymphocyte signaling. Rather than acting only as a microbial weapon, complement helps organize the overall architecture of immune defense.

4 Regulation of complement components

Because complement activation is powerful, it must be tightly controlled to avoid injury to host tissues. Regulation occurs at multiple stages and in different compartments, including plasma and the cell surface. These controls limit spontaneous amplification and confine activity to appropriate targets.

4.1 Fluid-phase regulators

Soluble regulators circulate in plasma and act on complement components before or after they associate with surfaces. Their main role is to restrain amplification in the fluid phase and to promote inactivation of deposited fragments. This keeps background activity under control.

4.1.1 Factor H

Factor H is a key regulator of the alternative pathway. It binds C3b and accelerates decay of the alternative pathway convertase, while also serving as a cofactor for factor I-mediated cleavage. Its activity is especially important on host surfaces that display markers of self.

By favoring inactivation on appropriate surfaces, factor H helps distinguish self from nonself. It is therefore a major determinant of alternative pathway specificity.

4.1.2 Factor I

Factor I is a serine protease that cleaves C3b and C4b only in the presence of cofactors such as factor H or membrane-bound regulators. This cleavage converts active fragments into inactive forms and prevents further amplification. Factor I is essential for limiting complement deposition.

Its action provides a biochemical off switch for the cascade. Without this regulatory step, complement activation would spread more widely and persist longer than is normally safe.

4.2 Membrane-bound regulators

Cell-surface regulators protect host tissues from complement attack. They operate close to the site of activation and are therefore especially effective at preventing damage to self membranes. Different regulators act at different stages of the cascade.

4.2.1 CD46

CD46 serves as a cofactor for factor I and helps inactivate deposited C3b and C4b on host cells. It is broadly expressed on many cell types. By supporting fragment inactivation, CD46 helps maintain a noninjurious surface environment.

4.2.2 CD55

CD55, also known as decay-accelerating factor, destabilizes complement convertases. This reduces ongoing cleavage of C3 and limits further cascade progression. CD55 is particularly important for controlling amplification on cell surfaces.

4.2.3 CD59

CD59 inhibits membrane attack complex formation by blocking the incorporation of C9 into the developing pore. This protects host cells from terminal complement-mediated lysis. It is one of the most direct defenses against complement-induced membrane damage.

4.3 Control of cascade amplification

Regulation is especially important at amplification points such as C3 convertase formation. Small amounts of activation can otherwise expand rapidly through positive feedback. The combined action of soluble and membrane-bound regulators keeps this amplification focused and transient.

This control system allows complement to remain responsive while minimizing bystander injury. In normal physiology, activation and restraint operate together as complementary parts of the same defense network.

5 Complement components and disease

Alterations in complement proteins can lead to increased susceptibility to infection, abnormal inflammation, or tissue injury. Disease may arise from inherited deficiencies, acquired dysregulation, or excessive activation. Because complement is distributed widely in blood and tissues, its dysfunction can have diverse clinical consequences.

5.1 Complement deficiencies

Inherited or acquired deficiencies of specific complement components can impair immune defense. The clinical pattern depends on which protein is missing and where it acts in the cascade. Some deficiencies mainly affect pathogen clearance, while others interfere with immune complex handling.

5.1.1 Recurrent infections

Defects in early classical, lectin, or terminal pathway components may increase vulnerability to particular infections. Terminal pathway deficiencies are classically associated with impaired defense against certain encapsulated bacteria. In other cases, reduced opsonization can weaken phagocytic clearance of microbes.

The clinical presentation varies, but repeated or unusually severe infections are a common clue. Recognition of the pattern often prompts evaluation of complement function.

5.1.2 Immune complex disorders

When complement-mediated clearance is inadequate, immune complexes may persist and deposit in tissues. This can contribute to inflammatory injury in organs such as the kidneys, joints, or skin. Reduced early classical pathway activity is especially relevant because of its role in immune complex processing.

Complement deficiency therefore may not only weaken host defense but also impair removal of antigen-antibody complexes. The result is an increased risk of immune complex-related pathology.

5.2 Excessive activation and tissue injury

Uncontrolled complement activity can damage host cells and amplify inflammation. This may occur when regulatory proteins are defective or when complement is activated intensely in a localized tissue environment. Excessive deposition of complement fragments can promote cell injury, edema, and inflammatory cell influx.

Such injury reflects the same mechanisms that normally protect against pathogens. When regulation fails, however, the system’s potency becomes a liability rather than an advantage.

5.3 Laboratory evaluation of complement activity

Complement function can be assessed with functional assays that measure pathway integrity. Screening tests may evaluate overall hemolytic activity or pathway-specific activity, while component assays quantify individual proteins. These studies help identify deficiencies, consumption, or abnormal activation.

Laboratory interpretation often depends on the clinical context. Reduced activity may indicate a missing component, accelerated consumption, or impaired production, and targeted follow-up tests are often needed to distinguish among these possibilities.

5.4 Therapeutic targeting of complement

Complement is an active area of therapeutic development because it offers multiple intervention points. Strategies include blocking convertase formation, inhibiting terminal pathway assembly, or reducing inappropriate activation upstream. Such approaches aim to preserve useful host defense while limiting inflammatory damage.

Therapies that target complement are generally designed for carefully selected conditions in which abnormal complement activity is a major driver of disease. The diversity of complement components makes the system amenable to precise pharmacologic control.

6 Biosynthesis and distribution

Complement proteins are distributed throughout the body, but most are produced in specific tissues and released into the circulation. Their abundance in plasma allows rapid deployment when an immune trigger appears. Tissue expression also contributes to local regulation and specialized functions.

6.1 Hepatic production

The liver is the main source of many complement proteins. Hepatocytes synthesize large amounts of C3, C4, C5, and several regulatory factors. This supports the high plasma concentrations needed for fast and broad immune responses.

Liver production provides a steady systemic supply. Because complement proteins are consumed during activation, continuous synthesis is necessary to maintain functional reserve.

6.2 Circulating plasma levels

Most complement components are present in plasma at measurable baseline levels. Their inactive state allows them to circulate without causing continuous damage. Upon activation, these proteins are rapidly recruited into the cascade.

The relatively high concentration of many complement proteins helps ensure prompt response to infection or injury. At the same time, regulation prevents this abundance from translating into uncontrolled activity.

6.3 Tissue and cell-surface expression

Some complement proteins and regulators are expressed locally by cells outside the liver. Endothelial cells, epithelial cells, leukocytes, and other tissues can contribute to localized complement control. Cell-surface regulators are particularly important at interfaces exposed to blood or environmental surfaces.

Local expression allows tissues to tailor complement activity to their specific needs. This distributed arrangement complements the systemic pool found in plasma.

7 Experimental and clinical applications

Complement has become an important tool in both laboratory research and medical practice. It is used to study immune mechanisms, assess disease activity, and guide treatment design. Because the system is measurable and mechanistically well defined, it is a useful platform for translational work.

7.1 Diagnostic markers

Complement proteins and their cleavage products can serve as laboratory markers of immune activation. Patterns of consumption or deficiency may help indicate particular disease processes. Measurement of complement activity is therefore useful in evaluating immune-mediated disorders.

Markers are most informative when interpreted alongside clinical findings and other laboratory tests. They provide evidence of pathway involvement, but not always a complete explanation of the underlying condition.

7.2 Research models

Complement-deficient animals and cell-based systems are widely used to investigate innate immunity, inflammation, and host-microbe interactions. These models help define the contribution of individual components and regulatory proteins. They also support the development of therapies that target specific steps in the cascade.

Experimental systems have been especially valuable for studying convertases, regulators, and terminal pathway assembly. They allow researchers to separate pathway initiation from amplification and effector functions.

7.3 Complement-based therapeutics

Therapeutic approaches targeting complement include inhibitors of activation enzymes, blockers of terminal components, and agents that enhance regulation. These interventions are designed to modulate rather than abolish the system. The goal is to reduce harmful complement activity while preserving protective immune functions.

As understanding of complement biology has advanced, more selective strategies have become possible. This has expanded the system’s role from a subject of basic immunology to a practical target in precision medicine.